Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2014 May 20;2(8):812–821. doi: 10.1158/2326-6066.CIR-14-0013

Table 3.

Multivariate analysis of relationship between m-MDSC and overall survival at pre-treatment baseline and week 6 after ipilimumab treatment.

Ipilimumab
Pre-treatment Week 6
n HR (95% CI) p-value n HR (95% CI) p-value
MDSC ≤ 14.9% 68 0.47 (0.23 – 0.94) 0.033 63 0.38 (0.18 – 0.81) 0.012
ALC ≥1000 cells/µl - - - 63 0.21 (0.10 – 0.46) < 0.001
LDH < 250 68 0.38 (0.21 – 0.69) 0.002 63 0.29 (0.15 – 0.56) < 0.001